Outcomes in Young Women With Breast Cancer of Triple-Negative Phenotype: The Prognostic Significance of CK19 Expression

Parikh, Rahul R.; Yang, Qifeng; Higgins, Susan A.; Haffty, Bruce G.

doi:10.1016/j.ijrobp.2007.05.066

Cited by 55 publications

(44 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, the Danish Breast Cancer Cooperative Group found a significantly increased local recurrence probability, whether or not receiving post-mastectomy radiation therapy (PMRT) [27]. The study by Parikh et al [28], however, included primarily node-negative patients (75%) treated with breast-conserving surgery and radiotherapy, whereas the DBCG82 b and DBCG82 c studies accrued primarily high-risk, node-positive patients (94%), all treated with mastectomy. Lack of CK19 expression (a luminal cytokeratin marker) is associated with a significantly higher risk of local relapse.…”

Section: Clinical Behaviour: Patterns Of Recurrence and Prognosismentioning

confidence: 99%

Triple-negative breast cancer

Stockmans

Deraedt²,

Wildiers³

et al. 2008

Current Opinion in Oncology

View full text Add to dashboard Cite

The recent advances in pathological and molecular knowledge have changed the landscape of breast cancer, with triple-negative breast cancer emerging as a pathological and clinical heterogeneous group. The main challenge lies in the development of new tailored treatment strategies for the various subgroups, with receptor kinase inhibition as the most promising new evolution to date. Further trials are needed to validate these new treatment options.

show abstract

Section: Clinical Behaviour: Patterns Of Recurrence and Prognosismentioning

confidence: 99%

Triple-negative breast cancer

Stockmans

Deraedt²,

Wildiers³

et al. 2008

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Specifically, molecular gene expression for estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu (HER-2) allows a higher order of classification that has been correlated to outcomes (4,5). Subsequently, the use of immunohistochemical analysis as a surrogate for molecular profiling has been verified to estimate the prevalence of these molecular subtypes (18,36), allowing for more widespread utilization of this higher order of tumor distinction in the clinical setting to provide important insight into management strategies and risk of distant metastasis (13,32). …”

Section: Introductionmentioning

confidence: 99%

Are Breast Cancer Subtypes Prognostic for Nodal Involvement and Associated with Clinicopathologic Features at Presentation in Early-Stage Breast Cancer?

Jones

Neboori

et al. 2013

Ann Surg Oncol

Self Cite

View full text Add to dashboard Cite

Purpose Breast cancer subtypes (BCS) determined from IHC staining have been correlated with molecular subtypes and associated with prognosis/outcomes, but there are limited data correlating these BCS and axillary node involvement. This study was conducted to assess whether BCS predicted for nodal metastasis or was associated with other clinical-pathologic features at presentation. Methods Stage I/II patients who underwent breast-conserving surgery and axillary surgical assessment with available tissue blocks underwent a institutional pathological review and construction of a tissue microarray(TMA). The slides were stained for ER/PR/HER2-neu for classification into BCS. Nodal involvement and other clinical-pathologic features were analyzed to assess associations between BCS and patient/tumor characteristics. Outcomes were calculated a function of BCS. Results The study cohort consisted of 453 patients(LA 48.6%, LB 16.1%, HER2 11.0%, TN 24.2%), of which 22%(n=113) were node+. There were no significant associations with BCS and pN stage, node positivity, or absolute number of nodes involved (all p>0.05). However, there were significant associations with subtype and age at presentation (< 0.001), method of detection (p=0.049), tumor histology (p<0.001), race (p=0.041), and tumor size (pT stage, p<0.001) by univariate and multivariate analysis. As expected, 10-year outcomes differed by BCS, with TN & HER2/neu subtypes having the worse overall(p=0.03), disease-free(p=0.03) and distant metastasis-free survival(p< 0.01). Conclusions Our findings suggest that there is a significant association between BCS and age, T stage, histology, method of detection and race, but no associations to predict nodal involvement. If additionally validated, these findings suggest that BCS should not strongly influence regional management considerations.

show abstract

“…Parikh et al [15] reported that patients with ipsilateral breast tumor recurrence events of the basal-like phenotype have a poor prognosis despite receiving standard chemotherapy. It is reported that anthracyclines, alkylating agents, taxanes, cisplatin, or proteasome inhibitors induce apoptosis in part by activation of the JNK pathway [16,17].…”

Section: Introductionmentioning

confidence: 99%